Case 1:14-cv-01453-LPS Document 90-1 Filed 02/26/16 Page 1 of 49 PageID #: 1955
`Case 1:14—cv—O1453—LPS Document 90-1 Filed 02/26/16 Page 1 of 49 Page|D #: 1955
`
`EXHIBIT A
`
`

`
`Case 1:14-cv-01453-LPS Document 90-1 Filed 02/26/16 Page 2 of 49 PageID #: 1956
`9“||l|||1||1|II11I|1I||1lllllllllllllll|1111l1||flf11l1|1IflI||||F56
`
`US008l63723B2
`
`(12) United States Patent
`Lulla et al.
`
`(10) Patent N0.:
`(45) Date of Patent:
`
`US 8,163,723 B2
`Apr. 24, 2012
`
`(54) COMBINATION OF AZELASTINE AND
`STEROIDS
`
`(75)
`
`Inventors: Amar Lulla, Mumbai (IN); Geena
`Malhotra, Mumbai (IN)
`
`(73) Assignee: CIPLA Limited, Mumbai (IN)
`
`( * ) Notice:
`
`Subject to any disclaimer, the term of this
`patent is extended or adjusted under 35
`U.S.C. 154(b) by 77 days.
`
`(21) Appl.No.: 12/879,515
`
`(22)
`
`Filed:
`
`Sep. 10, 2010
`
`(65)
`
`Prior Publication Data
`
`US 2010/0331289 A1
`
`Dec. 30, 2010
`
`Related U.S. Application Data
`
`filed as
`(62) Division of application No. 10/518,016,
`application No. PCT/GB03/02557 on Jun. 13, 2003.
`
`(30)
`
`Foreign Application Priority Data
`
`Jun. 14, 2002
`
`(GB) ................................. .. 0213739.6
`
`(51)
`
`Int. Cl.
`(2006.01)
`A61K 31/55
`(52) U.S. Cl.
`..................................................... .. 514/171
`(58) Field of Classification Search ...................... .. None
`See application file for complete search history.
`
`(56)
`
`References Cited
`
`U.S. PATENT DOCUMENTS
`
`2,837,464 A
`3,067,197 A
`3,312,590 A
`3,506,694 A
`3,557,162 A
`3,639,434 A
`3,755,302 A
`3,828,080 A
`3,856,828 A
`3,891,631 A
`3,981,894 A
`3,989,686 A
`4,093,721 A
`4,113,680 A
`4,187,301 A
`4,188,385 A
`4,198,403 A
`4,221,787 A
`4,261,984 A
`4,263,289 A
`4,267,173 A
`4,285,937 A
`4,310,466 A
`4,335,121 A
`4,377,575 A
`4,472,393 A
`
`6/1958 Nobile
`12/1962 Agnello et al.
`4/1967 Elks et al.
`4/1970 Oxley
`1/1971 Voorschoten et al.
`2/1972 Oxley et al.
`8/1973 Ercoliet al.
`8/1974 Mayet al.
`12/1974 Phillipps et al.
`6/1975 Phillipps et al.
`9/1976 Phillipps et al.
`11/1976 Phillipps et al.
`6/1978 Phillipps et al.
`9/1978 Kamano et al.
`2/1980 Edwards
`2/1980 Edwards
`4/1980 Alvarez
`9/1980 Bodor et al.
`4/1981 Alvarez
`4/1981 Edwards
`5/1981 Draper
`8/1981 Kalvoda
`1/1982 Edwards
`6/1982 Phillipps et al.
`3/1983 Stache etal.
`9/1984 Shapiro
`
`4,607,028 A
`4,710,495 A
`4,861,765 A
`4,992,474 A
`4,994,439 A
`4,996,335 A
`5,063,222 A
`5,081,113 A
`5,164,194 A
`5,202,316 A
`5,232,919 A
`5,271,946 A
`5,362,721 A
`5,420,120 A
`5,608,093 A
`5,658,549 A
`5,658,919 A
`5,707,984 A
`5,837,699 A
`5,849,265 A
`5,889,015 A
`5,914,122 A
`5,972,920 A
`5,981,517 A
`6,017,963 A
`6,057,307 A
`6,127,353 A
`6,136,294 A
`6,197,761 B1
`6,261,539 B1
`6,294,153 B1
`6,319,513 B1
`6,330,938 B1
`6,391,340 B1
`6,395,300 B1
`6,416,743 B1
`6,525,228 B2
`
`8/1986 Schmidlin
`12/1987 Bodor
`8/1989 Mitsukuchi et al.
`2/1991 Skidmore et al.
`2/1991 Longnecker et al.
`2/1991 Bodor
`11/1991 Komoto et al.
`1/1992 Claussner et al.
`11/1992 Hettche
`4/1993 Claussner et al.
`8/1993 Scheffler et al.
`12/1993 Hettche
`11/1994 Stache et al.
`5/1995 Boltralik
`3/1997 Stache et al.
`8/1997 Akehurst et al.
`8/1997 Ratnaraj et al.
`1/1998 Tjoeng et al.
`11/1998 Sequeira et al.
`12/1998 Li-Bovet et al.
`3/1999 Sequeira et al.
`6/1999 Otterbeck et al.
`10/1999 Seidel
`11/1999 Bodor
`1/2000 Alfonso et al.
`5/2000 Sequeira et al.
`10/2000 Yuen et al.
`10/2000 Adjei et al.
`3/2001 Biggadike et al.
`7/2001 Adjei et al.
`9/2001 Modi
`11/2001 Dobrozsi
`12/2001 Herve et al.
`5/2002 Malmqvist-Granlund et al.
`5/2002 Straub et al.
`7/2002 Fassberg et al.
`2/2003 Chauvin et al.
`
`(Continued)
`
`AU
`
`FOREIGN PATENT DOCUMENTS
`2003244799 B2
`12/2003
`
`(Continued)
`
`OTHER PUBLICATIONS
`
`Office Action (Final) dated Feb. 18, 2011 (23 pages), U.S. Appl. No.
`12/508,388, filed Jul. 23, 2009.
`
`(Continued)
`
`Primary Examiner — Johann Richter
`Assistant Examiner — Thor Nielsen
`
`(74) Attorney, Agent, or Firm — Conley Rose, P.C.; Rodney
`B. Carroll
`
`(57)
`
`ABSTRACT
`
`A pharmaceutical product or formulation, which comprises
`azelastine or a pharmaceutically acceptable salt, solvate or
`physiologically functional derivative thereof, and a steroid, or
`a pharmaceutical acceptable salt, solvate or physiologically
`functional derivative thereof, preferably the product or for-
`mulation being in a form suitable for nasal or ocular admin-
`istration.
`
`28 Claims, No Drawings
`
`

`
`Case 1:14-cv-01453-LPS Document 90-1 Filed 02/26/16 Page 3 of 49 PageID #: 1957
`Case 1:14—cv—O1453—LPS Document 90-1 Filed 02/26/16 Page 3 of 49 Page|D #: 1957
`
`US 8,163,723 B2
`Page 2
`
`U.S. PATENT DOCUMENTS
`
`3/2003 Biggadike etal.
`6,537,983 B1
`6/2003 Linketal.
`6,583,180 B2
`9/2004 Biggadike et al.
`6,787,532 B2
`7/2005 Cuenoud et al.
`6,921,757 B2
`9/2006 Biggadike et al.
`7,101,866 B2
`7/2007 Pieperetal.
`7,244,742 B2
`8/2010 Pairetetal.
`7,776,315 B2
`5/2002 Osbakken etal.
`2002/0061281 A1
`6/2002 Kaplanetal.
`2002/0076382 A1
`6/2002 Woolfe etal.
`2002/0081266 A1
`8/2002 Stache etal.
`2002/0103392 A1
`11/2002 Biggadike etal.
`2002/0165211 A1
`11/2002 Biggadike
`2002/0173496 A1
`11/2002 Biggadike
`2002/0177581 A1
`1/2003 Meadeetal.
`2003/0018019 A1
`4/2003 Biggadike etal.
`2003/0073676 A1
`6/2003 Biggadikeetal.
`2003/0109511A1
`7/2003 Biggadike etal.
`2003/0144257 A1
`8/2003 Cuenoudetal.
`2003/0158163 A1
`3/2004 Komoto etal.
`2004/0053904 A1
`7/2004 Garrett etal.
`2004/0136918 A1
`10/2004 Osbakken etal.
`2004/0204399 A1
`11/2004 Weinrich etal.
`2004/0235807 A1
`12/2004 Yarmietal.
`2004/0242638 A1
`7/2005 Miyadia et al.
`2005/0163724 A1
`9/2005 Jost-Price et al.
`2005/0192261 A1
`2/2006 Lullaetal.
`2006/0025391 A1
`5/2006 Dangetal.
`2006/0110331 A1
`10/2006 Lane
`2006/0228306 A1
`1/2007 Dangetal.
`2007/0020330 A1
`11/2009 Myles et al.
`2009/0286762 A1
`11/2009 Lullaetal.
`2009/0291143 A1
`12/2009 Lullaetal.
`2009/0318397 A1
`6/2010 Fuge etal.
`2010/0152147 A1
`FOREIGN PATENT DOCUMENTS
`
`BE
`DE
`DE
`DE
`DE
`E1’
`E1’
`E1’
`E1’
`E1’
`E1’
`EP
`EP
`EP
`G13
`G13
`G13
`G13
`G13
`G13
`G13
`G13
`GB
`IL
`JP
`JP
`
`JP
`11’
`$8
`W0
`W0
`W0
`$8
`W0
`W0
`W0
`W0
`W0
`WO
`
`889563 A
`1059900
`3830579 A1
`19947234 A1
`10152369 A1
`0004773
`0057401
`0179583
`0393058
`0410951
`0780127
`0780127 A1
`1519731 B1
`2072051 A1
`1191905
`1290458
`1384372
`1438940
`1517278
`2079755
`2088877
`2140800
`2389530 A
`109656
`04208267
`8291072
`
`8291073
`2002'053485
`
`9104252
`9214472
`9531964
`9619199
`9701337 A1
`9705 136
`9715298
`9721721
`9721724
`9724365
`
`11/1981
`0/ 1959
`5/ 1989
`9/1999
`5/2002
`10/ 1979
`8/ 1982
`4/ 1980
`10/ 1990
`3/ 1991
`0/ 1997
`6/1997
`4/2009
`6/2009
`5/ 1970
`11/ 1972
`2/ 1975
`0/ 1970
`7/ 1978
`1/ 1982
`0/ 1982
`12/ 1984
`12/2003
`2/1998
`7/ 1992
`11/1996
`
`11/1995
`2/2002
`
`4/1991
`9/1992
`11/1995
`1671996
`1/1997
`2/ 1997
`571997
`6/1997
`6/1997
`7/1997
`
`W0
`
`$8
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`wo
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`
`08
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`24
`
`9740836
`
`9811904712 A1
`9834596
`9848839 A1
`9901467
`9925359
`9932089
`0016814
`0033892
`0038811
`0048587
`0049993
`0066522
`0104118
`0120331
`0154481
`0154664
`0157025
`0162722
`0178736
`0178739
`0178741
`0178745
`0200199
`0200079
`0202565
`0207757
`0203243
`0212265
`0212266
`0213868
`0226723
`0236106
`02051422
`02053185
`02066422
`02070490
`
`8383332
`02088167
`02100879
`03000241
`03013427
`03033000
`03035668
`03040691
`03042229
`03042230
`03048181
`03062259
`03064445
`03066033
`03066036
`03066656
`03072592
`03086399
`03105856 A1
`2004013156
`2004019955 A1
`2008012338 A2
`872389
`
`11/1997
`
`1471998
`871998
`11/1998
`171999
`571999
`771999
`372000
`672000
`772000
`872000
`872000
`1172000
`172001
`372001
`872001
`872001
`872001
`872001
`1072001
`1072001
`1072001
`1072001
`172002
`172002
`1/2002
`1/2002
`1/2002
`2/2002
`2/2002
`2/2002
`4/2002
`5/2002
`7/2002
`7/2002
`8/2002
`9/2002
`
`18/388%
`11/2002
`12/2002
`172003
`272003
`4/2003
`5/2003
`5/2003
`5/2003
`5/2003
`6/2003
`772003
`872003
`872003
`8/2003
`8/2003
`9/2003
`10/2003
`12/2003
`2/2004
`3/2004
`1/2008
`471987
`
`OTHER PUBLICATIONS
`
`Oflice Action (Final) dated Feb. 24, 2011 (20 pages), U.S. Appl. No.
`12/508,393, filed Jul. 23, 2009.
`Oflice Action dated Feb. 16, 2011, (22 pages), U.S. Appl. No.
`10/518,016, filed Jul. 6, 2005.
`Office Action dated Sep. 30, 2010, U.S. Appl. No. 12/508,388, filed
`Jul. 23, 2009, 22 pages.
`Office Action dated Sep. 30, 2010, U.S. Appl. No. 12/508,393, filed
`J“1'23.’2°99’31}?ag9S'
`.
`.
`.
`.
`.
`.
`.
`Schmidt, M. W., The new topical steroid ciclesonide is effective in
`the treatment of allergic rhinitis,” Journal of Clinical Pharmacology,
`1999,vo1. 39, pp. 1062-1069
`Malhotra Exhibit B, Aug. 2011.
`Maus Exhibit B, Aug. 2011.
`
`

`
`Case 1:14-cv-01453-LPS Document 90-1 Filed 02/26/16 Page 4 of 49 PageID #: 1958
`Case 1:14-cv-01453-LPS Document 90-1 Filed 02/26/16 Page 4 of 49 Page|D #: 1958
`
`US 8,163,723 B2
`Page 3
`
`Nielsen, et al., “Intranasal corticosteroids for allergic rhinitis: supe-
`rior relief?” Drugs, 2001, vol. 61, No. 11, pp. 1535-1691.
`Opponent’s R116 Submission for EP1519731, 2011.
`CIPLA’s response to Statement of Opposition for EP1519731, 2011.
`Shenfield, “Fixed drug combinations: which ones can be recom-
`mended?” Current Therapeutics, 1986, pp. 15-29.
`Opponent’s Statement of Opposition for EP1519731, 2011.
`Result of oral proceedings dated Oct. 12, 2011 of EP Patent No.
`1 5 1973 1 .
`Opponent’s submission dated Oct. 6, 2011 to EP Patent No. 1519731.
`Patentee’s submission dated Oct. 5, 2011 to EP Patent No. 1519731.
`Patentee’s submission dated Sep. 29, 2011 regarding list of attendees
`at oral proceedings on EP Patent No. 1519731.
`Opponent’s submission dated Sep. 23, 2011 regarding list of attend-
`ees at oral proceedings on EP Patent No. 1519731.
`Opponent’s submission dated Sep. 23, 2011 regarding additional
`documents on EP Patent No. 1519731.
`Patentee’s submission dated Sep. 19, 2011 on EP Patent No.
`1 5 1973 1 .
`Patentee’s response of Sep. 6, 2010 of EP Patent No. 1519731.
`Hampel, Frank C., et al., Double-blind, placebo-controlled study of
`azelastine and fluticasone in a single nasal spray delivery device,
`Annals ofAllergy, Asthma & Immunology, Aug. 2010, vol. 105, pp.
`168-173.
`to the Editor, “Fluticasone fi1roate/
`Biggadike, Keith, Letter
`fluticasone propionate—different drugs with different properties,”
`The Clinical Respiratory Journal, 2011, pp. 183-184.
`Rapid response report: summary with critical appraisal, fluticasone
`furoate versus fluticasone propionate for seasonal allergic rhinitis: a
`review of the clinical and cost-effectiveness,
`Jun. 13, 2011,
`Fluticasone Furoate for Seasonal Allergic Rhinitis.
`Office Action dated Sep. 9, 2011 ofU.S. Appl. No. 12/508,388, filed
`Jul. 23,2009.
`Office Action dated Sep. 15,2011 ofU.S.Appl.No. 12/508,393, filed
`Jul. 23,2009.
`Search Report dated May 12, 2009 of EP 09075101.
`Search Report dated May 12, 2009 of EP 09075100.
`Mealy, N. E., et al., “Ciclesonide:
`treatment of allergic rhinitis
`antiallergy/antiasthmatic,” Drugs of the Future, Prous Science, ES,
`vol. 26, No. 11, Nov. 2001, pp. 1033-1039.
`Office Action dated Jul. 11, 2011—20632 IL.
`Office Action dated Aug. 31, 2010 (6 pages), U.S. Appl.
`12/374,523, filed Jan. 21, 2009.
`Applicants’ response dated Oct. 6, 2010 (8 pages) in U.S. Appl. \Io.
`12/374,523, filed Jan. 21, 2009.
`Office Action dated Nov. 30, 2010 (16 pages), U.S. Appl. \Io.
`12/374,523, filed Jan. 21, 2009.
`Applicants’ response dated Feb. 24, (2010) 2011 (8 pages) in U.S.
`Appl. No. 12/374,523, filed Jan. 21, 2009.
`Office Action (Final) dated May 3, 2011 (8 pages), U.S. Appl. \Io.
`12/374,523, filed Jan. 21, 2009.
`Applicants’ response dated Jun. 22, 2011 (9 pages) in U.S. Appl. \Io.
`12/374,523, filed Jan. 21, 2009.
`Notice of Non-responsive Amendment dated Jul. 6, 2011 (3 pages),
`U.S. Appl. No. 12/374,523, filed Jan. 21, 2009.
`Applicants’ response dated Sep. 6, 2011 (8 pages) in U.S. Appl. \Io.
`12/374,523, filed Jan. 21, 2009.
`Spector, Sheldon, “Ideal pharmacotherapy for allergic rhinitis,” J
`Allergy Clin Immunol, vol. 103, No. 3, Part 2, pp. S386-S387, 1999.
`Duonase Data Sheet, “The complete rhinitis control,” 6 pages, Cipla
`Limited, Mumbai, India, 2004.
`Product Specification Bulletin, Avicel® RC-591, Bulletin AVC591-
`SPEC-02/09.RS, 2 pages, FMC BioPolymer, Feb. 2009.
`Product Specification Bulletin, Avicel® CL-611, Bulletin AVC611-
`SPEC02/09.RS, 2 pages, FMC BioPolymer, Feb. 2009.
`File history of Brazilian Patent Application No. PI 0312128-3, 27
`pages, Apr. 2011.
`File history ofCanadian Patent Application No. 2,489,427, 19 pages,
`Dec. 2010.
`File history of Polish Patent Application No. P-373001, 95 pages,
`May 201 1 .
`File history of Russian Patent Application No. RU 2361593 C2, 65
`pages, Apr. 2009.
`
`\Io.
`
`Notice ofAllowance dated Oct. 3, 2011 (33 pages) in U.S. Appl. No.
`10/518,016, filed Jul. 6, 2005.
`Salib, et al., “Safety and Tolerability Profiles of Intranasal
`Anihistaminese and Intranasal Corticosteroids in the Treatment of
`Allergic Rhinitis,” Drug Safety; 2003; vol. 26, No. 12, pp. 829-911.
`Office Action dated Apr. 7, 201 1 (3 pages) from counterpart applica-
`tion, AU2009243420.
`Product Information, Nasonex®, Aug. 2001, 22 pages, Schering
`Corporation, Kenilworth, NJ, US.
`Product Specification Bulletin, Avicel® RC-591, Bulletin AVC591-
`SPEC-02/09.RS, 2 pages, FMC BioPolymer.
`Product Specification Bulletin, Avicel® CL-61 1, Bulletin AVC611-
`SPEC-02/09.RS, 2 pages, FMC BioPolymer.
`Ratner, Paul H., et al., “Combination therapy with azelastine hydro-
`chloride nasal spray and fluticasone propionate nasal spray in the
`treatment of patients with seasonal allergic rhinitis,” Annals of
`Allergy, Asthma & Immunology, Jan. 2008, vol. 100, Cover page,
`publishing page, pp. 74-81.
`Ratner, Paul H., et al., “A Comparison of the Efficacy of Fluticasone
`Propionate Aqueous Nasal Spray and Loratadine, Alone and in Com-
`bination, for the Treatment of Seasonal Allergic Rhinitis,” The Jour-
`nal of Family Practice, Aug. 1998, vol. 47, No. 2, pp. 118-125,
`Appleton & Lange.
`Reddy, Indra K., ed., “Ocular Therapeutics and Drug Delivery: A
`Multi-Disciplinary Approach,” 1996, pp. 382-385 plus cover page
`and publication page, Technornic Publishing Company, Inc.
`Safety Data Sheet, SDS No. 110556, Jul. 4, 2008, V14, Flonase Nasal
`Spray, 5 pages, GlaxoSmithKline.
`Safety Data Sheet, SDS No. 110536, Jun. 23, 2008, V13, Beconase
`Hayfever Allergy Spray, 5 pages, GlaxoSmithKline.
`Salib Rami Jean, et al., “Safety and Tolerability Profiles of Intranasal
`Antihistamines and Intranasal Corticosteroids in the Treatment of
`Allergic Rhinitis,” Drug Safety 2003, vol. 26, No. 12, Cover page,
`publication page, pp. 863-893, ADIS Data Information BV.
`Simpson, Richard J., “Budesonide and terfenadine, separately and in
`combination, in the treatment of hay fever,” Annals of Allergy, Dec.
`1994, vol. 73, Cover page, publication page, pp. 497-502.
`Spector, Sheldon, “Ideal pharmacotherapy for allergic rhinitis,” J
`Allergy Clin Immunol, 1999, vol. 103, No. 3, Part 2, pp. S386-S387,
`Mosby, Inc..
`Wang, De-Yun, “Treatment of Allergic Rhinitis: H1-Antihistamines
`and Intranasal Steroids,” Current Drug Targets—Inflammation &
`Allergy, 2002, vol. I, pp. 215-220, Bentham Science Publishers Ltd.
`Wiseman, Lynda R., et al., “Intranasal Fluticasone Propionate: A
`Reappraisal of its Pharmacology and Clinical Efficacy in the Treat-
`ment of Rhinitis,” Drugs, 1997, vol. 53, No. 5, pp. 885-907, Adis
`International Limited.
`1 Interna-
`World Review 2001: The Pharmaceutical Market, vol.
`tional, IMC Health, 2001, cover, preface, and copyright pages plus
`pp. 4-42 and 5-1 through 5-11, IMS A.G.
`Applicant Response to foreign communication EP Patent 1519731,
`Aug. 11, 2011, 252 pages.
`“Azelastine,” STN Registry No. 58581-89-8, STN Registry File,
`Retrieved Nov. 23, 2010, p. 1.
`“Fluticasone Furoate,” STN Registry No. 397864-44-7, STN Regis-
`try File, Retrieved Nov. 23, 2010, p. 1.
`Astepro (azelastine HCI) Nasal Spray 0.15%, Meda Pharmaceuticals
`Inc., 2009, Press Release, pp. 1-4.
`Aigbirhio, Franklin I., et al., “Automated radiosynthesis of no-car-
`rier-added
`[S-fluoromethyl-18F]Fluticasone
`propionate
`as
`a
`radiotracer for lung deposition studies with PET,” Journal of Labelled
`Compounds and Radiopharmaceuticals, vol. 39, No. 7, 1997, pp.
`569-584.
`Austin, et al., “Mometasone filroate is a less specific glucocorticoid
`than fluticasone propionate,” Eur. Respir. J., 2002, vol. 20, pp. 1386-
`1392.
`Banov, et al., “Once daily intranasal fluticasone propionate is effec-
`tive for perennial allergic rhinitis,” Annals of Allergy, 1994, vol. 73,
`pp. 240-246.
`Baumgarten, C., et al., “Initial treatment of symptomatic mild to
`moderate bronchial
`asthma with the
`salmeterol/fluticasone
`propionate (50/250ug) combination product (SAS 40023),” Euro-
`pean Journal of Medical Research, 2002, vol. 7, pp. 1-7.
`
`

`
`Case 1:14-cv-01453-LPS Document 90-1 Filed 02/26/16 Page 5 of 49 PageID #: 1959
`Case 1:14-cv-01453-LPS Document 90-1 Filed 02/26/16 Page 5 of 49 Page|D #: 1959
`
`US 8,163,723 B2
`Page 4
`
`Berstein, et al., “Treatment with intranasal fluticasone propionate
`significantly improves ocular syrnptons in patients with seasonal
`allergic rhinitis,” Clin. Exp. Allergy, 2004, vol. 34, pp. 952-957.
`Brooks, et al., “Spectrum of seasonal allergic rhinitis symptom relief
`with topical corticoid and oral antihistamine given singly or in com-
`bination,” American Journal of Rhinology, 1996, vol. 10, No. 3, pp.
`193-199.
`Bryson, et al., “Intranasal fluticasone propionate: a review of its
`pharmacodynamic and pharmacokinetic properties, and therapeutic
`potential in allergic rhinitis,” Drugs, 1992, vol. 43, No. 5, pp. 760-
`775.
`Busse, William, et al., “Steroid-sparing effects of fluticasone
`propionate 100ug and salmeterol 50 ug administered twice daily in a
`single product in patients previously controlled with fluticasone
`propionate 250 ug administered twice daily,” J. Allergy Clin.
`Immunol., vol. 111, No. 1, Jan. 2003, pp. 57-65.
`CAS Registry No. 102113-40-6, 2004.
`CAS Registry No. 90566-53-3, “Fluticasone,” Nov. 16, 1984.
`Chapman, et al., “Anti-inflammatory activity of inhaled mometasone
`furoate in allergic mice,” Arzneimettelforschung (“Drug Research”),
`1998, vol. 48, No. 4, pp. 384-391.
`fluticasone
`Daley-Yates,
`et
`al.,
`“Systemic bioavailability of
`propionate administered as nasal drops and aqueous nasal spray
`formulations,” Br. J. Clin. Pharmocol., 2001, vol. 51, pp. 103-105.
`Derby, et al., “Risk of cataract among users of intranasal
`corticosteroids,” J. Allergy Clin. Immunol., 2000, vol. 105, No. 5, pp.
`912-916.
`Dewester, et al., “The efficacy of intranasal fluticasone propionate in
`relief of ocular symptoms associated with seasonal rhinitis,” Allergy
`and Asthma Proc., 2003, vol. 24, No. 5, pp. 331-337.
`Dictionary of Organic Compounds, 6th Ed., vol. 1, p. 3234, definition
`of “fluticasone,” Chapman & Hall, 1996.
`Dolovich, et al., “Multicenter trial of fluticasone propionate aqueous
`nasal spray in ragweed allergic rhinitis,” Annals ofAllergy, 1994, vol.
`73, No. 2, pp. 147-153.
`Fowler, Stephen J., et al., “Step-down therapy with low-dose
`fluticasone-salmeterol
`combination
`or
`medium-dose
`hydrofluoroalkane 134a-beclomethasone alone,” J. Allergy Clin.
`Immunol., vol. 109, No. 6, Jun. 2002, pp. 929-935.
`Garner, R. C., et al., “A validation study comparing accelerator MS
`and liquid scintillation counting for analysis of 14C-labelled drugs in
`plasma, urine and faecal extracts,” Journal of Pharmaceutical and
`Biomedical Analysis, vol. 24, 2000, pp. 197-209.
`Gawchik, et al., “Comparison of intranasal triamcinolone acetonide
`with oral loratadine in the treatment of seasonal ragweed-induced
`allergic rhinitis,” Am. J. Man. Care, 1997, vol. 3, No. 7, pp. 1052-
`1058.
`Harding, “The human pharmacology offluticasone propionate,” Res-
`piratory Medicine, 1990, vol. 84, Suppl. A, pp. 25-29.
`Howland, “Fluticasone propionate:
`topical or systemic effects?”
`Clinical and Experimental Allergy, 1996, vol. 26, Suppl. 3, pp. 18-22.
`Isogai, et al., “Binding affinities of mometasone furoate and related
`compounds including its metabolites for the glucocorticoid receptor
`ofrat skin tissue,” J. Steroid Biochem. Mol. Biol., 1993, vol. 44, pp.
`141-145.
`Johansson, Gunnar, et al., “Comparison of salmeterol/fluticasone
`propionate combination with budesonide in patients with mild-to-
`moderate asthma,” Clin. Drug Invest., vol. 21, No. 9, 2001, pp.
`633-642, 11 pages.
`Juniper, Elizabeth F., et al., “Impact of inhaled salmetero1/fluticasone
`propionate combination product versus budesonide on the health-
`related quality of life of patients with asthma,” Am. J. Respir. Med.,
`vol. 1, No. 6, 2002, pp. 435-440.
`Kenley, Richard A., et al., “An automated, column-switching HPLC
`method for analyzing active and excipient materials in both cream
`and ointment formulations,” Drug Development and Industrial Phar-
`macy, vol. 11 (9 & 10), 1985, pp. 1781-1796.
`Kertesz, Denis J., et al., “Thiol esters from steroid 17[3-carboxylic
`acids: carboxylate activation and internal participation by 17
`oi-acylates,” J. Org. Chem., vol. 51, 1986, 14 pages.
`Kooreman, et al., “The synthesis of 17-esters of corticosteroids pro-
`tection of 11[3-hydroxyl of the trimethylsilyl group,” Synthetic Com-
`munications, vol. 1, No. 2, pp. 81-87, 1971.
`
`Laforce, et al., “Fluticasone propionate: an effective alternative treat-
`ment for seasonal allergic rhinitis in adults and adolescents,” J. Fam.
`Pract., 1994, vol. 38, No. 2, pp. 145-152.
`new capillary
`a
`of
`Lane,
`S.
`J.,
`et
`al.,
`“Evaluation
`electrochromatography/mass spectrometry interface using short col-
`urrms and high field strengths for rapid and efficient analyses,” Rapid
`Communications in Mass Spectrometry, vol. 10, 1996, pp. 733-736.
`Lewis, Sarah A., eta1., “Association of specific allergen sensitization
`with socioeconomic factors and allergic disease in a population of
`Boston women,” J. Allergy Clin. Immunol., vol. 107, No. 4, Apr.
`2001, pp. 615-622.
`Li, et al., “Synthesis of aryl 5-(2-chlorophenyl)-2-furoates under
`phase transfer catalysis,” Synthetic Communications, vol. 32, No. 20,
`pp. 3081-3086, 2002.
`Linder, “Symptom scores as measurements of the severity of
`rhinitis,” Clinical Allergy, 1988, vol. 18, pp. 29-37.
`Lutsky, et al., “A novel class of potent topical antiinflamrnatory
`agents: 17-benzolyated, 7a-halogeno substituted corticosteroids,”
`Arzneimettelforschung (“Drug Research”), 1978, vol. 29, No. 1 1, pp.
`1662-1667.
`Lyseng-Williamson, Katherine A., et al., “Inhaled salmetero1/
`fluticasone propionate combination in chronic obstructive pulmo-
`nary disease,”Am. J. Respir. Med., vol. 1, No.4, 2002, pp. 273-282.
`Mahoney, Janette M., et al., “Drug effects on the neovascularization
`response to silver nitrate cauterization ofthe rat cornea,” Current Eye
`Research, vol. 4, No. 5, 1985, pp. 531-535.
`Millard, Jeffrey W., et al., “Solubilization by cosolvents establishing
`useful constants
`for
`the log-linear model,” Int’1 Journal of
`Pharmeceutics, vol. 245, 2002, pp. 153-166.
`Mistry, Nisha, et al., “Characterisation of impurities in bulk drug
`batches of fluticasone propionate using directly coupled HPLC-
`NMR spectroscopy and HPLC-MS,” Journal of Pharmaceutical and
`Biomedical Analysis, vol. 16, 1997, pp. 697-705.
`Mistry, Nisha, et al., “Impurity profiling in bulk pharmaceutical
`batches using 19F NMR spectroscopy and distinction between
`monomeric and dimeric impurities by NMR-based diffusion mea-
`surements,” Journal ofPharmaceutical and Biomedical Analysis, vol.
`19, 1999, pp. 511-517.
`Moreno-Vargas, et al., “Synthesis and gylcosidase inhibitory activi-
`ties of 5-(1',4‘-dideoxy-1‘,4’-imino-D-erythrosyl)-2-methyl-3-fi1roic
`acid (:5-[(3S,4R)-3,4-dihydroxypyrrolidin-2-yl]-2methy1furan-3-
`carboxylic acid) derivatives: new leads as
`selective alpha-L-
`fucosidase and beta-galactosidase inhibitors,” Helvetica Chimica
`Acta, vol. 86, pp. 1894-1913, 2003.
`Nathan, et al., “A once daily fluticasone proprionate aqueous nasal
`spray is an effective treatment for seasonal allergic rhinitis,” Annals
`ofAllergy, 1991, vol. 67, pp. 332-338.
`Nelson, Harold, S., et al., Fluticasone propionate-salmeterol combi-
`nation provides more effective asthma control than low-do se inhaled
`corticosteroid plus montelukast, J. Allergy Clin. Immunol., vol. 106,
`No. 6, Dec. 2000, pp. 1088-1095.
`Ong, John T. H., et al., “Micellar solubilization oftimobesone acetate
`in aqueous and aqueous propylene glycol solutions of nonionic
`surfactants,” Pharmaceutical Research, vol. 5, No. 11, 1988, pp.
`704-708.
`Ong, John T. H., et al., “Intrinsic potencies of novel thiol ester
`corticosteroids RS-85095 and RS-21314 as
`compared with
`clobetasol 17-propionate and fluocinonide,” Arch Dermatol, vol.
`125, Dec. 1989, pp. 1662-1665.
`Onrust, et al., “Mometasone furoate, a review of its intranasal use in
`allergic rhinitis,” Drugs, vol. 56, No. 4, Oct. 1998, pp. 725-745, vol.
`21.
`Pettersson, Bertil, et al., “Re-evaluation of the classical mycoplasma
`lipophilum cluster (Weisburg, et al., 1989) and description of two
`new clusters in the hominis group based on 16S rDNA sequences,”
`Int’1 Journal of Systematic & Evolutionary Microbiology, 2001, vol.
`51, pp. 633-643.
`Phillips, G. H., et al., “Synthesis and structure activity relationships
`in a series of anti-inflammatory corticosteroid analogues, halomethyl
`androstane—17B-carbothioates and—17B-carboselenoates,” Jour-
`nal of Medicinal Chemistry, 1994, vol. 37, pp. 3717-3729.
`Product Information Flonase (Fluticasone proprionate) Nasal Spray
`50 mcg, 2004, pp. 1-13.
`
`

`
`Case 1:14-cv-01453-LPS Document 90-1 Filed 02/26/16 Page 6 of 49 PageID #: 1960
`Case 1:14-cv-01453-LPS Document 90-1 Filed 02/26/16 Page 6 of 49 Page|D #: 1960
`
`US 8,163,723 B2
`Page 5
`
`Product Information Rhinocort Aqua (budesonide) Nasal Spray 32
`mcg, 2005, pp. 1-2.
`Sakagami, et al., “Mucoadhexive BDP microspheres for powder
`inhalation—their unique pharmacokinetic-pharmacodynamic pro-
`files,” Respiratory Drug Delivery, vol. VI, pp. 193-199, 1998.
`Sandham, et al., “Synthesis and biological properties of novel
`glucocorticoid androstene C-17 filroate esters,” Bioorganic &
`Medicinal Chemistry, 2004, vol. 12, pp. 5213-5224.
`Scadding, et al., “Clinical and physiological effects of fluticasone
`propionate aqueous nasal spray in the treatment ofperennial rhinitis,”
`Rhinology, 1991, Suppl. 11, pp. 37-43.
`Settipane, et al., “Triamcinolone acetonide aqueous nasal spray in
`patients with seasonal ragweed allergic rhinitis: a placebo -controlled,
`double-blind study,” Clin. Ther., 1995, vol. 17, No. 2, pp. 252-263.
`Shapiro, et al., “17-esters and 17,21-diesters of 9-alpha, 11-beta-
`dichlorocorticoids. Synthesis and anti-inflammatory activity,” Ste-
`roids, vol. 9, No. 2, pp. 143-156, 1967.
`Shapiro,
`et
`al.,
`“Synthesis and structure-activity studies of
`corticosteroid 17-heterocyclic aromatic esters. 1. 9-alpha, 11-beta
`dichloro series,” Journal of Medicinal Chemistry, vol. 30, No. 6, pp.
`1068-1073, 1987.
`Shapiro, et al., “17 heteroaroyl esters of corticosteroids 2. 11 beta
`hydroxy series,” Journal of Medicinal Chemistry, American Chemi-
`cal Society, Washington, US, vol. 30, No. 9, 1987, pp. 1581-1588.
`Smith, et al., “In vitro glucocorticoid receptor binding and transcrip-
`tional
`activiation
`by
`topically
`active
`glucocorticoids,”
`Arzneimettelforschung, 1998, 48(II)(9), pp. 956-959.
`Smith, N., et al., “Comparison ofthe electroosmotic flow profiles and
`selectivity
`of
`stationary
`phases
`used
`in
`capillary
`electrochromatography,” Journal of Chromatography A., vol. 832,
`1999, pp. 41-54.
`Souness, et al., “Immunosuppressive and anti-inflammatory effects
`of cyclic AMP phosphodiesterase (PDE)
`type 4 inhibitors,”
`Immunopharmacology, 2000, vol. 47, Nos. 2/3, pp. 127-162.
`Stempel, et al., “Treatment of allergic rhinitis: an evidence-based
`evaluation of nasal corticosteroids versus nonsedating antihista-
`mines,” Am. J. Man. Care, 1998, vol. 4, pp. 89-96.
`Study No. 03DMW062—“Pharmacokinetics of GW685698X and
`CC118781 (fluticasone propionate) when co-administered by the
`intratracheal or intravenous route to the anaesthetised white pig,”
`2004.
`Study No. B30947—“The Pharmacokinetics of GW685698X and
`CC118781
`following
`intratracheal
`co-administration to
`the
`anaesthetised white pig,” 2003.
`Szefler, Stanley J., et al., Chapter 21, “Glucocorticoids in severe
`asthma: mechanisms of action and route of administration,” Difficult
`Asthma, pp. 371-375, Martin Dunitz Ltd., Informa Health Care,
`1999.
`Togashi, et al., 9-fluoro-11B, 17, 21-trihyrdroxy-16a-methyl-1,4-
`pregnadiene-3,
`20 -dione
`2 1 -cyclohexanecarboxylate
`17-cyclopropanecarboxylate (ST126); Oyo Yakuri, 2002, vol. 63,
`No. 5/6, pp. 61-77.
`Undem, et al., “Neural integration and allergic disease,” J. Allergy
`Clin. Immunol., 2000, vol. 106, No. 5, pp. S213-S220.
`The United States Pharmacopoeia, 23rd Ed., US Pharmacopoeia
`Convention, Inc., Rockville MD, 1995, pp. 1843-1844, “Physical
`Tests / (941) X-Ray Diffraction”
`Van AS, et al., “Once daily flluticasone propionate is as effective for
`perennial
`allergic
`rhinitis
`as
`twice
`daily beclomethasone
`dipropionate,” J. Allergy Clin. Immunol., 1993, vol. 91, No. 6, pp.
`1 146-1 154.
`Van Bavel, et al., “Ocular efficacy and clinician overall evaluation of
`intranasal fluticasone proprionate (FP) versus loratadine (LOR) in
`seasonal allergic rhinitis (SAR),” Annals of Allergy, Asthma, &
`Immunology, 1997, vol. 78, p. 128, Abstract P101.
`Wenkert, et al., “Short syntheses of furan and catechol derivatives. A
`synthesis of hydrourushiol1,2,” Journal American Chemical Society,
`vol. 105, pp. 2021-2029, 1983.
`Westlund, et al., “Fluticasone propionate aqueous nasal spray 200 mg
`once daily provides relief of ocular symptoms associated with sea-
`sonal allergic rhinitis,” 57th Annual Meeting of the American Acad-
`emy of Allergy, Asthma and Immunology, New Orleans LA, Mar.
`16-21, 2001, Abstract No. 522.
`
`they
`
`Woodford, et al., “Activity and bioavailability of a new steroid
`(Timobesone acetate) in cream and ointment compared with Lidex
`and Dermovate creams and ointments and Betnovate cream,” Int’1
`Journal ofPharmaceutics, 1985, vol. 26, pp. 145-155.
`Observations on patentability of the object of the patent application
`PV 2003-352 (Czech Republic), 2003.
`Notice of Oppo sition to the grant ofpatent on Patent Application No.
`762/2001 (140397) (Pakistan), 2010.
`(report shows that
`CIPLA Annual Report Extract; 2010;
`launched an FF+azelastine product in 2010).
`Declaration ofGeena Malhotra for EP1519731 dated Aug. 11, 2011.
`Declaration of Joachim Maus for EP1519731 dated Aug. 10, 2011.
`Vanrell, “Preservatives in ophthalmic formulations: an overview,”
`Arch. Soc. Esp. Oftalmol., 2007, vol. 82, pp. 531-532.
`Malhotra Exhibit A, Aug. 2011.
`ABPI Data Sheet Compendium, 1995-96, cover page plus pp. 38-39,
`Datapharm Publications Limited, London, Great Britain.
`Akerlund, Anders, et al., “Clinical trial design, nasal allergen chal-
`lenge models, and considerations of relevance to pediatrics, nasal
`polyposis, and different classes of medication,” J. Allergy Clin.
`Immunol., Mar. 2005, vol. 115, No. 3, pp. S460-S482.
`Applicants
`response to foreign communication—KR10-2004-
`7020819, Dec. 27, 2010, 18 pages.
`Applicants response to foreign communication—EP 03738280.1
`(EP Patent 1519731) , Sep. 6,2010, 15 pages.
`Applicants response to foreign communication—CA 2489427, Dec.
`20, 2010, 10 pages.
`Avicel® RC/CL, Microcrystalline Cellulose and Carboxymethylcel-
`lulose Sodium, NF Dispersible Cellulose, BP, Specifications and
`Analytical Methods, RC-16 Updated Oct. 1995 (Feb. 1999), 6 pages,
`FMC BioPolymer.
`Opposition to EP 1518731, Aug. 8, 2011, 19 pages.
`Aurora, Jack, “Nasal Delivery; Development of Nasal Delivery Sys-
`tems: A Review,” Drug Delivery Technology, vol. 2, No. 7, Oct. 2002,
`8 pages, http://www.drugdelivelytech.com/ME2/Segments/Publica-
`tions: Artic1e&id:9EB19EB2F29F462089CE081473F5F3CA.
`Baena-Cagnani, Carlos E ., “Safety and Tolerability ofTreatments for
`Allergic Rhinitis in Children,” Drug Safety 2004, vol. 27, No. 12, pp.
`883-898, ADIS Data Information BV.
`Barnes, M. L., et al., “Effects of levocetirizine as add-on therapy to
`fluticasone in seasonal allergic rhinitis,” Clinical and Experimental
`Allergy, Jan. 27, 2006, vol. 36, pp. 676-684, Blackwell Publishing
`Ltd.
`Berge, Stephen M., et al., “Pharmaceutical Salts,” Journal of Phar-
`maceutical Sciences, vol. 66, No. 1, Jan. 1977, pp. 1-19.
`Block, John H., et al., “Inorganic Medicinal and Pharmaceutical
`Chemistry,” 1986, cover, publication, and preface pages plus p. 100,
`Indian Edition, Varghese Publishing House, Bombay, India.
`Cipla Sixty-Ninth Annual Report 2004-2005, cover pages, informa-
`tion page, plus pp. 3, 5, and 44.
`Di Lorenzo, G., et al., “Randomized Placebo-controlled Trial Com-
`paring fluticasone aqueous nasal spray in mono-therapy, fluticasone
`plus cetirizine, fluticasone plus montelukast and cetirizine plus
`montelukast for seasonal allergic rhinitis,” Clin. Exp. Allergy, 2004,
`vol. 34, pp. 259-267., Blackwell Publishing Ltd.
`Duonase Data Sheet, “The Complete Rhinitis Control,” 6 pages,
`Cipla Limited, Mumbai, India.
`Drouin, Michel A., et al., “Adding Loratadine to Topical Nasal Ste-
`roid Therapy Improves Moderately Severe Seasonal Allergic
`Rhinoconjunctivitis,”Advances in Therapy, vol. 12, No. 6, Nov./Dec.
`1995, pp. 340-349, Health Communications Inc.
`File history ofAustralian Pa